Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in Rest of World: $484M in FY2025, up 2.1% from a year earlier.
Latest, FY2025
484
Period ended Dec 31, 2025
Change on a year earlier
+2.1%
474 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Sandostatin Group | Established brands | Carcinoid tumors, acromegaly | 729 | -9 | 484 | 2 | 2 | 1 213 | -5 | -5”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in Rest of World ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 484 | +2.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 474 | -2.3% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 485 | +10.7% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 438 | -23.2% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 570 | -5.3% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 602 | -14.5% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 704 | -8.6% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2018 | Dec 31, 2018 | 770 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up net Sales in Rest of World
Cite this data
StockData. (2026). Novartis Net Sales in Rest of World ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-sandostatin-group-row-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.